Palbociclib 100mg: Clinical Trials

2 trials of Palbociclib 100mg, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Terminated 1
Phase 11Terminated 1

Follow Palbociclib 100mg: new trials by email Literature Review of Palbociclib 100mg trials Research Report on Palbociclib 100mg

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Palbociclib 75mg, Letrozole 2.5mg, T-DM1 - HER2-positive Breast Cancer, Breast Cancer Metastatic
Phase 1 / Phase 2TerminatedUniversity of Kansas Medical Center32018-10-152024-03-05
Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
Palbociclib 100mg, Palbociclib 125mg, Fulvestrant or Tamoxifen or Aromatase Inhibitor - Breast Cancer
Phase 2CompletedCanadian Cancer Trials Group1802016-04-082026-04-13

Conditions studied

Breast Neoplasms (1)

Sponsors

Canadian Cancer Trials Group (1)  ·  University of Kansas Medical Center (1)

Countries

Canada (1)  ·  United States (1)

Top investigators

Anil A. Joy (1)  ·  Lauren Nye, MD (1)

Results publications

PMID 41123599